You are currently browsing the archives for 1 July 2018.
Displaying 1 - 2 of 2 entries.

Baxter enters definitive contract to acquire Prism Baxter International Inc.

The transaction is likely to close in the next quarter of 2011, at the mercy of customary closing circumstances and expiration of the waiting around period beneath the Hart-Scott-Rodino Antitrust Improvements Action. This transaction isn’t likely to have a materials effect on Baxter’s 2011 economic outcomes. The NEXTERONE premixed IV formulations had been recently accepted by the FDA in two ready-to-make use of dosage forms: 150 mg in a 100 mL flexible container for speedy 10-minute loading infusion and 360 mg in a 200 mL versatile container for subsequent loading and maintenance infusions. These ready-to-use formats need no admixing, removing potential medicine errors connected with compounding. Furthermore, NEXTERONE could be stored at space heat range during its two 12 months shelf life and ties in automated dispensing cupboards and crash carts, placing the merchandise in patient treatment areas ready for make use of during acute, time delicate and life-threatening situations.

Patients in every treatment groupings continued using NSAIDs through the entire trial.

Array BioPharma announces excellent results from ARRY-797 Phase 2 trial on osteoarthritis Array BioPharma today announced that ARRY-797 met its primary endpoint in a randomized, placebo-controlled and active-controlled Phase 2 medical trial in 157 osteoarthritis patients experiencing moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs . Patients in every treatment groupings continued using NSAIDs through the entire trial. The investigational compound, ARRY-797, is definitely a novel, oral, selective p38 inhibitor with a mechanism of action unique from that of currently approved pain medications.